Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477762 · ClinicalTrials.gov registry record · NA
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 165
- Enrollment target
NCT01477762: Completed NA study, sponsored by Emory University.
NCT01477762 is a NA study that has completed, run by Emory University. The registered enrollment target is 165 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01477762, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 165 participants
- Enrollment target
Study Summary
Posttraumatic stress disorder (PTSD) occurs in some people after exposure to events that cause extreme fear or helplessness. The incidence of war zones worldwide and the prevalence of violence in large cities in the U.S., increases the likelihood that people will experience a traumatizing event in their lifetime. About 1 in 10 people who survive such events will develop PTSD, while most people will get better over time. This suggests that some people may have biological vulnerabilities that make it harder for them to recover. One of these biological risk factors may be related to how stress hormones work in people who get sick. Another is how people react to things that make them afraid or nervous, investigators have found that PTSD patients have higher than normal fear reactions. The part of the brain that reacts to fearful stimulation is linked to stress hormones; the purpose of this study is to examine how these systems interact. The study will suppress stress hormones (cortisol) production in one group of participants, while another will get a placebo. When their cortisol is suppressed, the participants will undergo a startle study to see if their fear responses are decreased. Investigators expect that people PTSD will show a normal fear response when their cortisol levels are reduced, similar to people without PTSD. This research can help discover new medicines for people with PTSD.
Primary Outcome
The study measured the acoustic startle response magnitude to a sudden noise using electromyography of the eyeblink muscle. This response magnitude was used as the individual's baseline to compare to the startle magnitude to the danger signal to see if fear conditioning had occurred.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-07 |
| Phase | NA |
What the finished NCT01477762 record still lists
NCT01477762 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01477762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01477762 about?
NCT01477762 is a clinical study titled "Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)". Posttraumatic stress disorder (PTSD) occurs in some people after exposure to events that cause extreme fear or helplessness. The incidence of war zones worldwide and the prevalence of violence in large cities in the U.S., increases the likelihood that people will experience a traumatizing event in t...
What is the current status of trial NCT01477762?
This trial is currently completed. It is a NA study. The enrollment target is 165 participants. The study started on 2011-11. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01477762?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01477762?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01477762's enrollment target sits among peer trials
165 626th of 2000 higher than 1,375 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia